Nanocarriers Loaded with Oxygen to Improve the Protection of the Heart to be Transplanted.

cyclic nigerosyl-nigerose hypoxia nanocarriers organ transplantation oxygen reoxygenation α-cyclodextrin α-cyclodextrin nanosponges

Journal

Current pharmaceutical design
ISSN: 1873-4286
Titre abrégé: Curr Pharm Des
Pays: United Arab Emirates
ID NLM: 9602487

Informations de publication

Date de publication:
2022
Historique:
received: 30 07 2021
accepted: 13 10 2021
pubmed: 10 11 2021
medline: 7 4 2022
entrez: 9 11 2021
Statut: ppublish

Résumé

In the case of serious cardiovascular diseases, such as refractory heart failure, heart transplantation is the only possible intervention. Currently, the modes of organ transport in hypothermic cardioplegic solution do not allow the implantation of the heart beyond 4-5 hours from the explant. The heart being an organ with a greater consumption of oxygen and high metabolism than the brain, its transport in hypothermic cardioplegic solutions presents critical issues in terms of time and conservation. An ambitious goal of many researchers and clinicians is to minimize the hypoxia of the explanted heart and extend the permanence time in cardioplegic solution without damage from hypoxia. Adequately oxygenating the explanted organs may extend the usability time of the explanted organ. This challenge has been pursued for years with approaches that are often expensive, risky, and/or difficult to use. We propose to consider oxygenated nanocarriers releasing oxygen for a long time. In this way, it will also be possible to use organs from distant countries with respect to the recipient, thus exceeding the canonical 4-5 hours tolerated up to now. In addition to the lack of oxygen, the transplanted organ can undergo the accumulation of catabolites due to the lack of perfusion during transport. Therefore, nanocarriers can also be perfused in adequate solution during organ transportation. A better oxygenation improving the postoperative recovery of the transplanted heart will improve the recipient's quality of life.

Identifiants

pubmed: 34751111
pii: CPD-EPUB-118770
doi: 10.2174/1381612827666211109112723
doi:

Substances chimiques

Cardioplegic Solutions 0
Oxygen S88TT14065

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

468-470

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Claudia Penna (C)

Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.
Istituto Nazionale Ricerche Cardiovascolari, 40126 Bologna, Italy.

Francesco Trotta (F)

Department of Chemistry, University of Turin, 10125 Turin, Italy.

Roberta Cavalli (R)

Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy.

Pasquale Pagliaro (P)

Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.
Istituto Nazionale Ricerche Cardiovascolari, 40126 Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH